If you are not happy with the results below please do another search
The advent of molecular biology techniques has revolutionized disease diagnosis. CLI discussed with Dr Chandrasekhar Nair from Molbio Diagnostics the benefit that these techniques have brought and how these technologies are being adapted for point-of-care use for rapid diagnosis and the benefit of rural populations. What has the impact of molecular biology been on disease […]
Labs working to combat Covid-19 will benefit from this initiative, as CytoSMART aims to reduce the huge workload currently facing researchers on projects vital to controlling the disease. CytoSMART’s unique and compact live-cell microscope films living cell cultures without disturbing their growth or behaviour. The device operates from inside cell culture incubators and is accessible […]
As the COVID-19 pandemic progresses in countries around the globe, there is an urgent need for rapid and reliable point-of-need detection testing. Dolomite Microfluidics and Mologic are working together to accelerate the development and launch of these tests. UK-based Mologic is a leading developer of rapid response diagnostic tests for diseases such as malaria and […]
Cambridge, UK-based Horizon Discovery Group, specializing in the application of gene editing and gene modulation for cell line engineering, has released an arrayed CRISPR knockout screening service for primary human B cells to its cell-based screening services. The new B cell screening service, the first of its kind in the market, will enable researchers to […]
OXGENE and The Native Antigen Company have joined forces to scale up production of SARS-CoV-2 (COVID-19) reagents by combining OXGENE’s proprietary Adenoviral Protein Machine Technology with The Native Antigen Company’s antigen development expertise. Together, OXGENE and The Native Antigen Company will aim to scale their antigen manufacturing capabilities to deliver high-purity, recombinant proteins for the […]
Roche will develop its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to SARS-CoV-2 and launch it in early May in countries accepting the CE mark. The company says it is actively working with the FDA for an Emergency Use Authorisation. The Elecsys Anti-SARS-CoV-2 immunoassay is an in vitro test, […]
The Netherlands-based Pharming Group, a specialty pharmaceutical company, have seen encouraging results from it RUCONEST (recombinant human C1 inhibitor) treatment in patients with confirmed COVID-19 infections. The patients were treated under a compassionate use program at the University Hospital Basel, Switzerland. Dr. Michael Osthoff, University Hospital Basel, Switzerland and the treating physician, said: “Although this […]
Waltham, MA–Nova Biomedical to host “COVID-19 Bedside Glucose Management: Risk of Ascorbic Acid and Hematocrit Interference,” a webinar led by Charbel Abou-Diwan, PhD, Director of Medical and Scientific Affairs, to help inform and support healthcare workers treating COVID-19 patients. Interest in the antioxidant properties of ascorbic acid use in critically ill patients is growing especially […]
Cobra Biologics (Cobra), an international contract development and manufacturing organization (CDMO) for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, announced 30 March they have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine […]
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, has supported CanSino Biologics Inc. (“CanSinoBIO”) and Maj. Gen. Chen Wei’s team at the Institute of Bioengineering at the Academy of Military Medical Sciences (“Institute of Bioengineering”) in China in their development of the first vaccine candidate against the novel coronavirus SARS-CoV-2 […]
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
